Accuracy of self-reported tobacco use in newly diagnosed cancer patients
- 389 Downloads
Accurate identification of tobacco use is critical to implement evidence-based cessation treatments in cancer patients. The purpose of this study is to evaluate the accuracy of self-reported tobacco use in newly diagnosed cancer patients.
Tobacco use questionnaires and blood samples were collected from 233 newly diagnosed cancer patients (77 lung, 77 breast, and 79 prostate cancer). Blood was analyzed for cotinine levels using a commercially available enzyme-linked immunosorbent assay. Patients with cotinine measurements exceeding 10 ng/mL were categorized as current smokers. Smoking status based upon cotinine levels was contrasted with self-report in current smokers, recent quitters (1 or less year since quit), non-recent quitters (>1 year since quit), and never smokers. Multivariate analyses were used to identify potential predictors of discordance between self-reported and biochemically confirmed smoking.
Cotinine confirmed 100 % accuracy in self-reporting of current and never smokers. Discordance in cotinine and smoking status was observed in 26 patients (15.0 %) reporting former tobacco use. Discordance in self-reported smoking was 12 times higher in recent (35.4 %) as compared with non-recent quitters (2.8 %). Combining disease site, pack-year history, and employment status predicted misrepresentation of tobacco use in 82.4 % of recent quitters.
Self-reported tobacco use may not accurately assess smoking status in newly diagnosed cancer patients. Patients who claim to have recently stopped smoking within the year prior to a cancer diagnosis and lung cancer patients may have a higher propensity to misrepresent tobacco use and may benefit from biochemical confirmation.
KeywordsTobacco Smoking Cotinine Accuracy Self report (self-report) Cancer Nicotine
The authors wish to thank Cheryl Rivard and Jennifer Graf for their assistance with data analysis and comments on earlier drafts of this paper. This work was supported in part by Roswell Park Cancer Institute, National Cancer Institute (NCI) grant #P30 CA016056, an American Cancer Society Mentored Research Scholar Grant (MRSG-11-031-01-CCE), and an American Cancer Society Institutional Research Grant.
Conflict of interest
Dr Cummings provides expert testimony against the tobacco industry.
- 1.U.S. Department of Health and Human Services (2004) The health consequences of smoking: a report of the Surgeon General. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GAGoogle Scholar
- 8.Boorjian S, Cowan JE, Konety BR et al (2007) Cancer of the prostate strategic urologic research endeavor investigators. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the prostate strategic urologic research endeavor. J Urol 177:883–887PubMedCrossRefGoogle Scholar
- 13.Goldberg JD (1975) The effects of misclassification on the bias in the difference between two proportions and the relative odds in the fourfold table. J Am Stat Assoc 70:561–567Google Scholar
- 26.Benowitz NL (2009) Biomarkers of environmental tobacco smoke exposure. Environ Health Perspect 107:349–355Google Scholar
- 32.Land SR, Cronin WM, Wickerham DL et al (2011) Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project p-1 breast cancer prevention trial. Cancer Prev Res (Phila) 4:1393–1400CrossRefGoogle Scholar
- 36.Warren GW, Kasza KA, Reid ME et al (2013) Smoking at diagnosis and survival in cancer patients. Int J Cancer 132:401–410Google Scholar